See the DrugPatentWatch profile for Ertapenem
The trade name for Ertapenem is Invanz [1].
Who Manufactures Invanz?
Invanz, containing Ertapenem, is manufactured by Merck & Co., Inc. [1].
What is Ertapenem Used For?
Ertapenem is an antibiotic used to treat various bacterial infections. These include moderate to severe infections of the skin and skin structure, intra-abdominal infections, community-acquired pneumonia, and infections of the pelvis and female reproductive system [2]. It is also used for preventing infections following certain types of colon and rectal surgery [2].
How Does Ertapenem Work?
Ertapenem is a carbapenem antibiotic. It works by inhibiting the synthesis of bacterial cell walls, which leads to bacterial death [3]. This mechanism makes it effective against a broad spectrum of bacteria [3].
When Does Ertapenem's Patent Expire?
Information on specific patent expiry dates for Ertapenem can be found through resources like DrugPatentWatch.com [4]. Generally, brand-name drug patents have a finite lifespan, after which generic versions can be produced.
Can Generic Ertapenem Be Made?
Once patents and other forms of exclusivity expire, generic versions of Ertapenem can be developed and marketed. This typically leads to lower drug prices. DrugPatentWatch.com tracks patent statuses and exclusivity periods for many medications, including Ertapenem [4].
What Are the Side Effects of Ertapenem?
Common side effects reported with Ertapenem include nausea, vomiting, diarrhea, headache, and injection site reactions [2]. Less common but serious side effects can occur, and patients should consult their healthcare provider for a complete list of potential adverse events [2].
How is Ertapenem Administered?
Ertapenem is administered intravenously or intramuscularly [2]. It is typically given once a day [2].
What is the Difference Between Ertapenem and Other Carbapenems?
While Ertapenem belongs to the carbapenem class, it has a narrower spectrum of activity compared to some other carbapenems like imipenem or meropenem. Specifically, Ertapenem is not considered reliable for treating infections caused by Pseudomonas aeruginosa, Enterococcus species, or Acinetobacter species [3].
Sources:
1. https://www.merck.com/
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020503s054,021177s017,021608s009lbl.pdf
3. https://www.ncbi.nlm.nih.gov/books/NBK519465/
4. https://drugpatentwatch.com/